Abandoned study: could a drug fix Chemo-Related kidney injury?

NCT ID NCT05702996

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test the drug eculizumab in cancer patients who developed kidney damage from the chemotherapy drug gemcitabine. The goal was to see if eculizumab could help the kidneys recover. However, the trial was withdrawn before any patients were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

eculizumab

What this could lead to

If it had worked, this could have pointed toward a treatment for a rare chemotherapy side effect that damages kidneys.

What could go wrong

The trial was withdrawn before enrolling anyone, so no results exist. It was a small pilot study, and eculizumab is expensive with infection risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thrombotic microangiopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amiens University Hospital

    Amiens, France

  • Rouen University Hospital

    Rouen, France